MX342907B - El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. - Google Patents

El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.

Info

Publication number
MX342907B
MX342907B MX2011012048A MX2011012048A MX342907B MX 342907 B MX342907 B MX 342907B MX 2011012048 A MX2011012048 A MX 2011012048A MX 2011012048 A MX2011012048 A MX 2011012048A MX 342907 B MX342907 B MX 342907B
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating lupus
patient
lupus
Prior art date
Application number
MX2011012048A
Other languages
English (en)
Spanish (es)
Other versions
MX2011012048A (es
Inventor
Johanne M Kaplan
Bruce L Roberts
William M Siders
Original Assignee
Genzyme Corp *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp * filed Critical Genzyme Corp *
Publication of MX2011012048A publication Critical patent/MX2011012048A/es
Publication of MX342907B publication Critical patent/MX342907B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
MX2011012048A 2009-05-13 2010-05-13 El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus. MX342907B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17792409P 2009-05-13 2009-05-13
PCT/US2010/034741 WO2010132683A1 (en) 2009-05-13 2010-05-13 Methods and compositions for treating lupus

Publications (2)

Publication Number Publication Date
MX2011012048A MX2011012048A (es) 2011-12-12
MX342907B true MX342907B (es) 2016-10-17

Family

ID=43085330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012048A MX342907B (es) 2009-05-13 2010-05-13 El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.

Country Status (12)

Country Link
US (2) US9617343B2 (https=)
EP (2) EP2429583A4 (https=)
JP (3) JP5834004B2 (https=)
KR (1) KR101800467B1 (https=)
CN (2) CN110179989B (https=)
AU (2) AU2010248935B2 (https=)
BR (1) BRPI1013927A2 (https=)
CA (1) CA2761885A1 (https=)
IL (1) IL216146A0 (https=)
MX (1) MX342907B (https=)
RU (1) RU2607022C2 (https=)
WO (1) WO2010132683A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
US20150073043A1 (en) * 2012-01-19 2015-03-12 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Use of phosphorylation pathway-related factor in regulating function of regulatory t cell
RU2019103573A (ru) * 2013-02-08 2019-03-15 Аллегени-Сингер Рисерч Инститьют Клеточно-связанные продукты активации комплемента в качестве диагностических биомаркеров волчанки в доклинической стадии
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
EP2986990B1 (en) * 2013-03-20 2018-08-15 F.Hoffmann-La Roche Ag Specific detection of rat antibodies in mouse serum
ES3063961T3 (en) 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CA3287539A1 (en) 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US7060802B1 (en) * 2000-09-18 2006-06-13 The Trustees Of Columbia University In The City Of New York Tumor-associated marker
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
WO2004042032A2 (en) * 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
WO2005042581A2 (en) 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
EP1755673B1 (en) 2004-04-12 2014-07-23 MedImmune, LLC Anti-il-9 antibody formulations and uses thereof
CN101443040A (zh) * 2006-03-16 2009-05-27 基因技术股份有限公司 用cd4抗体治疗狼疮的方法
CA2648581A1 (en) 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2007121233A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
GB0608054D0 (en) * 2006-04-24 2006-05-31 Isis Innovation Production and use of regulatory t cells
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
JP2009543579A (ja) * 2006-07-19 2009-12-10 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗炎症反応のための標的としてのＷＳＸ−１／ｐ２８
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
EP2998405B1 (en) * 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52

Also Published As

Publication number Publication date
EP2429583A1 (en) 2012-03-21
US20120070408A1 (en) 2012-03-22
CN110179989A (zh) 2019-08-30
KR101800467B1 (ko) 2017-11-22
AU2010248935A1 (en) 2011-11-17
AU2017201771A1 (en) 2017-04-06
EP3345620A1 (en) 2018-07-11
MX2011012048A (es) 2011-12-12
JP2012526846A (ja) 2012-11-01
US9617343B2 (en) 2017-04-11
BRPI1013927A2 (pt) 2016-04-05
CN102438654A (zh) 2012-05-02
IL216146A0 (en) 2012-01-31
KR20140014392A (ko) 2014-02-06
WO2010132683A1 (en) 2010-11-18
CN110179989B (zh) 2022-06-24
JP2015052021A (ja) 2015-03-19
EP2429583A4 (en) 2013-10-16
AU2010248935B2 (en) 2016-12-15
JP2017008106A (ja) 2017-01-12
US20170369583A1 (en) 2017-12-28
RU2607022C2 (ru) 2017-01-10
RU2011150495A (ru) 2013-06-20
CA2761885A1 (en) 2010-11-18
JP5834004B2 (ja) 2015-12-16
EP3345620B1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
MX342907B (es) El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
GB2471588A (en) Therapeutic peptidomimetic macrocycles
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
MY160041A (en) Compositions and methods for treating parasitic infections
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
EA201071421A1 (ru) Анти-flt3 антитела
SG166093A1 (en) Inhibitors of brutonæs tyrosine kinase
PH12017501075B1 (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
ATE540709T1 (de) Implantierbare medizinische vorrichtung mit partikelbeschichtung
NZ602220A (en) Antibodies with ph dependent antigen binding
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
TW201613969A (en) IL-17 binding proteins
UA101944C2 (ru) Композиции и способы применения для антител dickopf-1
NZ703668A (en) Complexes of il-15 and il-15ralpha and uses thereof
WO2012081898A3 (ko) 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
WO2008034076A3 (en) Cyclophosphamide in combination with immune therapeutics
WO2010132697A3 (en) Methods and compositions for treatment
UA101814C2 (ru) Фактор, задействованный в латентной инфекции герпесвирусом, и его применение
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
WO2014028668A3 (en) Stem cell enhancing therapeutics
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation

Legal Events

Date Code Title Description
FG Grant or registration